These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
210 related articles for article (PubMed ID: 34083676)
1. Inhibition of triple negative breast cancer metastasis and invasiveness by novel drugs that target epithelial to mesenchymal transition. Garcia E; Luna I; Persad KL; Agopsowicz K; Jay DA; West FG; Hitt MM; Persad S Sci Rep; 2021 Jun; 11(1):11757. PubMed ID: 34083676 [TBL] [Abstract][Full Text] [Related]
2. Eribulin mesilate suppresses experimental metastasis of breast cancer cells by reversing phenotype from epithelial-mesenchymal transition (EMT) to mesenchymal-epithelial transition (MET) states. Yoshida T; Ozawa Y; Kimura T; Sato Y; Kuznetsov G; Xu S; Uesugi M; Agoulnik S; Taylor N; Funahashi Y; Matsui J Br J Cancer; 2014 Mar; 110(6):1497-505. PubMed ID: 24569463 [TBL] [Abstract][Full Text] [Related]
3. The Antimicrobial Peptide Merecidin Inhibit the Metastasis of Triple-Negative Breast Cancer by Obstructing EMT via miR-30d-5p/Vimentin. Ma F; Song J; He M; Wang X Technol Cancer Res Treat; 2024; 23():15330338241281310. PubMed ID: 39267432 [No Abstract] [Full Text] [Related]
4. Suppression of triple-negative breast cancer metastasis by pan-DAC inhibitor panobinostat via inhibition of ZEB family of EMT master regulators. Rhodes LV; Tate CR; Segar HC; Burks HE; Phamduy TB; Hoang V; Elliott S; Gilliam D; Pounder FN; Anbalagan M; Chrisey DB; Rowan BG; Burow ME; Collins-Burow BM Breast Cancer Res Treat; 2014 Jun; 145(3):593-604. PubMed ID: 24810497 [TBL] [Abstract][Full Text] [Related]
5. Anti-EMT properties of CoQ0 attributed to PI3K/AKT/NFKB/MMP-9 signaling pathway through ROS-mediated apoptosis. Yang HL; Thiyagarajan V; Shen PC; Mathew DC; Lin KY; Liao JW; Hseu YC J Exp Clin Cancer Res; 2019 May; 38(1):186. PubMed ID: 31068208 [TBL] [Abstract][Full Text] [Related]
6. Antrodia camphorata inhibits epithelial-to-mesenchymal transition by targeting multiple pathways in triple-negative breast cancers. Hseu YC; Chang GR; Pan JY; Rajendran P; Mathew DC; Li ML; Liao JW; Chen WT; Yang HL J Cell Physiol; 2019 Apr; 234(4):4125-4139. PubMed ID: 30146779 [TBL] [Abstract][Full Text] [Related]
7. Inhibition of iNOS as a novel effective targeted therapy against triple-negative breast cancer. Granados-Principal S; Liu Y; Guevara ML; Blanco E; Choi DS; Qian W; Patel T; Rodriguez AA; Cusimano J; Weiss HL; Zhao H; Landis MD; Dave B; Gross SS; Chang JC Breast Cancer Res; 2015 Feb; 17(1):25. PubMed ID: 25849745 [TBL] [Abstract][Full Text] [Related]
8. Luteolin suppresses epithelial-mesenchymal transition and migration of triple-negative breast cancer cells by inhibiting YAP/TAZ activity. Cao D; Zhu GY; Lu Y; Yang A; Chen D; Huang HJ; Peng SX; Chen LW; Li YW Biomed Pharmacother; 2020 Sep; 129():110462. PubMed ID: 32768952 [TBL] [Abstract][Full Text] [Related]
9. Inhibition of ERRα suppresses epithelial mesenchymal transition of triple negative breast cancer cells by directly targeting fibronectin. Wu YM; Chen ZJ; Liu H; Wei WD; Lu LL; Yang XL; Liang WT; Liu T; Liu HL; Du J; Wang HS Oncotarget; 2015 Sep; 6(28):25588-601. PubMed ID: 26160845 [TBL] [Abstract][Full Text] [Related]
10. Fangjihuangqi Decoction inhibits MDA-MB-231 cell invasion in vitro and decreases tumor growth and metastasis in triple-negative breast cancer xenografts tumor zebrafish model. Guo Y; Fan Y; Pei X Cancer Med; 2020 Apr; 9(7):2564-2578. PubMed ID: 32037729 [TBL] [Abstract][Full Text] [Related]
11. Tamoxifen reverses epithelial-mesenchymal transition by demethylating miR-200c in triple-negative breast cancer cells. Wang Q; Cheng Y; Wang Y; Fan Y; Li C; Zhang Y; Wang Y; Dong Q; Ma Y; Teng YE; Qu X; Liu Y BMC Cancer; 2017 Jul; 17(1):492. PubMed ID: 28724364 [TBL] [Abstract][Full Text] [Related]
12. GSK3β regulates epithelial-mesenchymal transition and cancer stem cell properties in triple-negative breast cancer. Vijay GV; Zhao N; Den Hollander P; Toneff MJ; Joseph R; Pietila M; Taube JH; Sarkar TR; Ramirez-Pena E; Werden SJ; Shariati M; Gao R; Sobieski M; Stephan CC; Sphyris N; Miura N; Davies P; Chang JT; Soundararajan R; Rosen JM; Mani SA Breast Cancer Res; 2019 Mar; 21(1):37. PubMed ID: 30845991 [TBL] [Abstract][Full Text] [Related]
13. Suppression of KIF3A inhibits triple negative breast cancer growth and metastasis by repressing Rb-E2F signaling and epithelial-mesenchymal transition. Wang W; Zhang R; Wang X; Wang N; Zhao J; Wei Z; Xiang F; Wang C Cancer Sci; 2020 Apr; 111(4):1422-1434. PubMed ID: 32011034 [TBL] [Abstract][Full Text] [Related]
14. Combined niclosamide with cisplatin inhibits epithelial-mesenchymal transition and tumor growth in cisplatin-resistant triple-negative breast cancer. Liu J; Chen X; Ward T; Pegram M; Shen K Tumour Biol; 2016 Jul; 37(7):9825-35. PubMed ID: 26810188 [TBL] [Abstract][Full Text] [Related]
15. Inhibition of Notch1 reverses EMT and chemoresistance to cisplatin via direct downregulation of MCAM in triple-negative breast cancer cells. Zeng D; Liang YK; Xiao YS; Wei XL; Lin HY; Wu Y; Bai JW; Chen M; Zhang GJ Int J Cancer; 2020 Jul; 147(2):490-504. PubMed ID: 32020593 [TBL] [Abstract][Full Text] [Related]
16. Discovery of a natural small-molecule compound that suppresses tumor EMT, stemness and metastasis by inhibiting TGFβ/BMP signaling in triple-negative breast cancer. Di L; Liu LJ; Yan YM; Fu R; Li Y; Xu Y; Cheng YX; Wu ZQ J Exp Clin Cancer Res; 2019 Mar; 38(1):134. PubMed ID: 30898152 [TBL] [Abstract][Full Text] [Related]
17. Cardamonin, a chalcone, inhibits human triple negative breast cancer cell invasiveness by downregulation of Wnt/β-catenin signaling cascades and reversal of epithelial-mesenchymal transition. Shrivastava S; Jeengar MK; Thummuri D; Koval A; Katanaev VL; Marepally S; Naidu VGM Biofactors; 2017 Mar; 43(2):152-169. PubMed ID: 27580587 [TBL] [Abstract][Full Text] [Related]
18. Resveratrol enhances the sensitivity of FL118 in triple-negative breast cancer cell lines via suppressing epithelial to mesenchymal transition. Yar Saglam AS; Kayhan H; Alp E; Onen HI Mol Biol Rep; 2021 Jan; 48(1):475-489. PubMed ID: 33389483 [TBL] [Abstract][Full Text] [Related]
19. Profilin 2 (PFN2) promotes the proliferation, migration, invasion and epithelial-to-mesenchymal transition of triple negative breast cancer cells. Ling Y; Cao Q; Liu Y; Zhao J; Zhao Y; Li K; Chen Z; Du X; Huo X; Kang H; Chen Z Breast Cancer; 2021 Mar; 28(2):368-378. PubMed ID: 33047272 [TBL] [Abstract][Full Text] [Related]
20. Targeted imaging and inhibition of triple-negative breast cancer metastases by a PDGFRβ aptamer. Camorani S; Hill BS; Collina F; Gargiulo S; Napolitano M; Cantile M; Di Bonito M; Botti G; Fedele M; Zannetti A; Cerchia L Theranostics; 2018; 8(18):5178-5199. PubMed ID: 30429893 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]